2022 Aortic Heart Disease 
Circulation
MARCH 29, 2025
Background: Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. The patient cohort had mean age of 7711 years, was 47% female, and had mean aortic valve area 0.80.1
Dr. S. Venkatesan MD
APRIL 10, 2024
A 76-year-old woman with a history of double valve replacement (Aortic and mitral valves) for rheumatic heart disease, presented with acute dyspnea after a switch from Warfarin to LMWH before a planned bone marrow biopsy. Hence distal protection by an Aortic sentinel device or its equivalent (FilterWire EZ, Tri-guard) is a must.
Frontiers in Cardiovascular Medicine
FEBRUARY 27, 2024
Background Valvular heart disease is a major health concern worldwide. Bibliometric analysis of studies on managing patients with artificial heart valves has not been previously performed. Transcatheter aortic valve replacement was a current research hotspot, while anticoagulation management was a key area of interest.
DAIC
FEBRUARY 29, 2024
24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.
Circulation
NOVEMBER 11, 2024
134 patients were identified and were divided into two groups, those with 22q11 deletion syndrome (19 patients) and the control group (115 patients).
The British Journal of Cardiology
AUGUST 1, 2024
Genome-wide association and Mendelian randomisation studies have identified lipoprotein(a) (Lp[a]) as an emerging risk factor for calcific aortic stenosis and a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) in different ethnicities. HEART UK recommends Lp(a) measurement in specific ‘at-risk’ cohorts.
Dr. Paddy Barrett
SEPTEMBER 12, 2023
Everyone should have an Lp(a) blood test at least once, but this is an absolutely must-do test if you have an early family history of heart disease. However, that does not mean you cannot reduce the overall risk of early heart disease. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
Expert insights. Personalized for you.
45 
Let's personalize your content